FDA nominee Marty Makary tells HELP Committee he will review mifepristone data, reassess canceled vaccine advisory meeting and assess staffing

Dr. Marty Makary, President Trump’s nominee for commissioner of the Food and Drug Administration, told the Senate Health, Education, Labor and Pensions Committee during his confirmation hearing that he will “follow the independent scientific review process at the FDA” and pledged several near-term reviews if confirmed.

Makary told Chairman Bill Cassidy and members of the committee that he would review ongoing data collected under REMS (Risk Evaluation and Mitigation Strategy) for mifepristone and has “no preconceived plans to make changes” to current policy. He said he would meet with career scientists at FDA and consider convening external experts where needed. “You have my commitment to follow the independent scientific review process at the FDA,” Makary said during a line of questioning about medication abortion and the REMS process.

Why it matters: The nominee’s answers touch on several high-profile issues — access to medication abortion, transparency of vaccine advisory processes, agency staffing, and conflicts of interest — that shape public health regulation and public trust in federal health agencies.

Key commitments and exchanges - Mifepristone and REMS: Makary said he would review the full body of data collected under the REMS program, including ongoing safety monitoring, and declined to pre-judge that evidence. He added he had “no preconceived plans to make changes to the mifepristone policy.” Several senators pressed him to state whether he would maintain current access; Makary emphasized that his approach would be data-driven and conducted in consultation with FDA career scientists.

- Vaccine advisory committee (VRBPAC) meeting: Committee members said FDA canceled an annual advisory meeting that traditionally reviews influenza strains. Makary said he had not been involved in that decision and pledged to “reevaluate which sessions…could benefit from convening the advisory committee” and to restore transparency where the committee’s expertise is needed. Senator Patty Murray and others asked for an immediate reconvening; Makary said he would evaluate the decision with center leadership.

- Agency staffing and recent federal layoffs: Senators pressed Makary on recent agency staffing reductions reported across federal agencies and at FDA. Makary said he was not involved in prior personnel decisions and committed, if confirmed, to conduct an assessment of staffing and personnel needs to ensure career scientists and inspectors have the resources required to do their work.

- Conflicts of interest and ethics: Makary said he completed an Office of Government Ethics review, that he chose voluntarily to divest and resign from private holdings, and that he would abide by OGE-required recusals. “I chose voluntarily to divest and resign from everything,” he said at the hearing.

- Drug pricing, generics and biosimilars: Makary said he supports measures to accelerate approval pathways for generics and biosimilars, including options to speed biosimilar review where competition is inadequate. He also discussed other approaches to lowering drug prices, such as moving certain products over the counter where appropriate.

- Food safety, vaping and children’s nutrition: Senators raised flavored e-cigarettes and food additives. Makary said FDA enforcement and interagency cooperation (including DOJ) would be part of addressing illegal imported products and pledged to review chemicals in the food supply and school-lunch procurements if confirmed.

Other notable exchanges - Advisory committees and transparency: Several senators emphasized that advisory committee meetings provide public transparency and post-mortems; Makary said he supports expert input and a review of which issues merit full advisory meetings.

- Clinical trial diversity and drug shortages: Makary agreed on the importance of clinical-trial diversity and said the agency should play a role in mitigating drug shortages. He described interest in modernizing post-approval surveillance and in applying new tools, including AI, to help reviewers and post-market monitoring.

What the hearing did not resolve - No committee confirmation vote for Makary is recorded in the provided transcript. Several senators asked for additional written questions for the record; Makary agreed to follow up where appropriate.

Speakers - Marty Makary — Nominee for Commissioner, Food and Drug Administration; surgical oncologist and Johns Hopkins faculty (government nominee/academic) - Bill Cassidy — Chairman, Senate Committee on Health, Education, Labor and Pensions (government) - Patty Murray — U.S. Senator, member of the committee (government) - Rand Paul — U.S. Senator (government) - Susan Collins — U.S. Senator (government) - Lisa Murkowski — U.S. Senator (government) - Josh Hawley — U.S. Senator (government) - Tammy Baldwin — U.S. Senator (government) - Michael Hickenlooper — U.S. Senator (government) - Others who questioned or participated included Senators Hassan, Blunt Rochester, Murkowski, Husted, Markey and others listed in the hearing transcript.

Authorities and references cited during the hearing - REMS (Risk Evaluation and Mitigation Strategy) — referenced by Makary when discussing ongoing data collection and safety monitoring for mifepristone (type: regulation/policy). - VRBPAC (Vaccines and Related Biological Products Advisory Committee) — advisory committee whose annual meeting to recommend influenza strains was discussed (type: other/committee process). - Office of Government Ethics (OGE) — Makary referenced OGE review and recusals (type: policy/ethics). - Dobbs decision — referenced by senators in relation to changes in abortion policy context (type: court_case).

Actions - {"kind":"appointment","motion":"Confirmation hearing for Dr. Marty Makary to be Commissioner of the Food and Drug Administration","mover":"not applicable","second":"not applicable","vote_record":[],"tally":{},"outcome":"no_action","notes":"The transcript records the hearing and commitments; no committee confirmation vote is recorded in the provided excerpt."}

Discussion vs. decision - Discussion: Extensive questioning on mifepristone, VRBPAC cancellation, agency staffing and ethics. Senators pressed for immediate policy assurances on access to mifepristone and restoration of advisory committee meetings; Makary stressed a data-centered review process. - Direction/assignment: Makary committed to review REMS data for mifepristone, to reevaluate the need for convening VRBPAC in relation to influenza strain selection, and to assess FDA staffing and personnel resources if confirmed. - Formal action: No vote to confirm the nominee was recorded in the provided transcript.

Clarifying details - "REMS review": Makary described REMS as the mechanism requiring ongoing data collection and said ongoing REMS data should be reviewed prior to policy changes. - "VRBPAC cancellation": Committee members said the FDA canceled an annual advisory meeting that traditionally recommends influenza strains; Makary said he was not involved in that decision and would reassess with career leadership. - "OGE review and divestment": Makary said OGE reviewed his disclosures and that he voluntarily divested and resigned from outside positions or holdings. Specific amounts and holdings were described to OGE and are part of the formal disclosure process (figures not detailed in the transcript).

Proper names [{"name":"Food and Drug Administration","type":"agency"},{"name":"Marty Makary","type":"person"},{"name":"Bill Cassidy","type":"person"},{"name":"Patty Murray","type":"person"},{"name":"Office of Government Ethics","type":"agency"},{"name":"VRBPAC","type":"other"},{"name":"REMS","type":"policy"},{"name":"Johns Hopkins","type":"organization"},{"name":"GIP International Consortium","type":"organization"},{"name":"Elon Musk","type":"person"}]

Community relevance - Geographies: United States (national) - Funding sources discussed: user fees, federal appropriations (in context of staffing and user-fee funded positions) - Impact groups: patients seeking medication abortion, vaccine stakeholders, FDA career scientists and inspectors, people affected by drug shortages and high drug prices

Meeting context - Engagement level: high — the hearing covered multiple high-profile topics, many senators asked substantive questions, and the nominee gave repeated commitments to review data and policies. - Implementation risk: medium — Makary can review and recommend changes, but statutory, regulatory and career-scientist processes determine many outcomes. - History: Transcript references prior FDA decisions (2021 REMS changes for mifepristone) and the reported cancellation of the VRBPAC meeting.

Searchable tags ["Marty Makary","FDA nomination","mifepristone","REMS","VRBPAC","vaccine advisory committee","layoffs","agency staffing","OGE","divestment","biosimilars","drug pricing","vaping","food safety"]

Provenance - {"block_id":"block_2727.905-2740.29","local_start":0,"local_end":120,"evidence_excerpt":"Thank you, Doctor. Macari, for appearing before the committee. The Food and Drug Administration is tasked with overseeing everything from drugs that treat debilitating diseases to safeguards in The U. S. Food supply.","global_start":2727.905,"global_end":2740.29,"tc_start":"00:45:27","tc_end":"00:45:40","reason_code":"topicintro"} - {"block_id":"block_9157.025-9157.525","local_start":0,"local_end":48,"evidence_excerpt":"For any senators who wish to ask additional questions, questions for the record will be due tomorrow at 5PM. This concludes the hearing.","global_start":9157.025,"global_end":9157.525,"tc_start":"02:32:37","tc_end":"02:32:37","reason_code":"topicfinish"}

Salience - overall:0.82 - overall_justification:"Nominee responses affect national public-health policy (drug access and safety, vaccines, advisory transparency) and agency leadership; multiple senators pressed on urgent matters." - impact_scope:"national" - impact_scope_justification:"FDA policy and leadership decisions affect healthcare delivery and public-health responses across the United States." - attention_level:"high" - attention_level_justification:"Medicines, vaccines, and FDA oversight attract broad public and media attention." - novelty:0.45 - novelty_justification:"Nominee’s multiple public commitments and the recent cancellation of a longstanding advisory meeting are notable developments." - timeliness_urgency:0.75 - timeliness_urgency_justification:"The committee hearing and imminent staff and policy reviews are time-sensitive to upcoming flu-season guidance and ongoing debates about medication access." - legal_significance:0.50 - legal_significance_justification:"References to REMS, advisory committee practice, and OGE recusals tie to existing regulatory frameworks." - budgetary_significance:0.30 - budgetary_significance_justification:"Discussion of staffing, user fees and agency resources may affect program administration and budgets." - public_safety_risk:0.45 - public_safety_risk_justification:"Debates over medication access, vaccine-strain selection, and food/vaping safety have public-health implications." - affected_population_estimate:10000000 - affected_population_estimate_justification:"Broad population potentially affected by FDA policies on drugs, vaccines and food safety; estimate intended as illustrative, not precise." - affected_population_confidence:0.30 - affected_population_confidence_justification:"High-level policy affects many groups but direct counts depend on specific policy decisions." - decision_deadline:"not specified" - decision_deadline_justification:"Committee did not record a confirmation vote; questions for the record were requested with an immediate deadline." - policy_stage:"committee" - policy_stage_justification:"Nominee hearing stage prior to any committee confirmation vote or executive-branch implementation." - follow_up_priority:9 - follow_up_priority_justification:"High — nominee’s stated reviews and commitments (REMS, VRBPAC, staffing) warrant prompt monitoring and follow-up." - fact_check_risk:0.22 - fact_check_risk_justification:"Transcript contains several transcription variants of names and terms; factual claims (e.g., layoff counts) need verification beyond the hearing." - uncertainty:0.28 - uncertainty_justification:"Nominee pledged reviews rather than immediate policy changes; final outcomes depend on later analyses and decisions." - source_diversity:0.35 - source_diversity_justification:"Primary source is the committee hearing transcript with multiple senators questioning the nominee." - stakeholder_balance:0.40 - stakeholder_balance_justification:"Hearing included perspectives across party lines; stakeholders (patients, career scientists, industry) were represented in questioning." - alert_flags:["deadline_soon","missing_sources"] - alert_flags_justification:"Questions-for-the-record deadline and several topics where detailed source documents or data (REMS datasets, staffing lists) were requested." }],